Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-4 ...
Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early ...
Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events ---- ...
Sarepta Therapeutics and partner Roche have reported a second case of fatal liver failure with their Duchenne muscular dystrophy (DMD) gene therapy Elevidys and stopped using it to treat some patients ...
What can patients expect during an orthodontic consultation? A HelloNation article provides the answer, featuring insights from Dr. Michelle Mathieson of Harmony Orthodontics in Canton, GA. The ...
The FDA has launched a formal investigation into two reports of fatal acute liver failure in patients treated with Sarepta and Roche's Duchenne muscular dystrophy (DMD) gene therapy Elevidys. The two ...
Charles Ischi’s versatile laboratory tablet hardness testers in the P-Series offer you the latest technology, space-saving design and maximum flexibility. Tailor the basic hardness testers (P2-P5) to ...
Duchenne muscular dystrophy (DMD) causes muscle weakness that becomes more severe over time. While there is no cure, treatments can help slow the progression and manage symptoms and complications.
Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results